RxDoctor Payments Data

Jeffrey Denham, MD

Internal Medicine · Pasadena, CANPI 1477592806

Payments from drug & device makers

$8,327in general payments, 2019–2025

Across 436 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$1K
  • Pfizer$623
  • Abbott$570
  • Novartis$504
  • Lilly USA, LLC$498
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$8,327100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,327 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$39,611
Medicare patients
198
Services billed
594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$148,700
OzempicSemaglutide82$77,219
JardianceEmpagliflozin31$47,309
MounjaroTirzepatide28$29,286
XareltoRivaroxaban37$28,227
PrevacidLansoprazole11$8,984
Testosterone55$8,603
SynthroidLevothyroxine Sodium103$8,235
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,432
PremarinEstrogens, Conjugated13$6,997
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$5,827
Benicar HctOlmesartan/Hydrochlorothiazide14$5,484
Doxepin Hcl25$4,926
BelsomraSuvorexant11$4,597
NeurontinGabapentin11$4,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$623$157,065234 claims
Novo NordiskOzempic$345$77,21982 claims
Boehringer IngelheimJardiance$23$47,30931 claims
Lilly USA, LLCMounjaro$498$29,28628 claims
AbbVieSynthroid$1,278$8,235103 claims
GSKTrelegy Ellipta$438$7,43212 claims
MerckBelsomra$89$4,59711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →